Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 39.2% in December

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) was the recipient of a significant growth in short interest in December. As of December 30th, there was short interest totalling 156,200 shares, a growth of 39.2% from the December 15th total of 112,200 shares. Based on an average daily volume of 815,400 shares, the short-interest ratio is presently 0.2 days. Currently, 1.7% of the shares of the stock are sold short.

Allarity Therapeutics Stock Performance

NASDAQ:ALLR opened at $0.22 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.47 and a quick ratio of 0.47. Allarity Therapeutics has a 12-month low of $0.20 and a 12-month high of $9.67. The firm has a 50-day moving average price of $0.34 and a 200 day moving average price of $0.81.

Allarity Therapeutics (NASDAQ:ALLR – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.42). Equities research analysts predict that Allarity Therapeutics will post -2.17 earnings per share for the current year.

Institutional Trading of Allarity Therapeutics

An institutional investor recently bought a new position in Allarity Therapeutics stock. Renaissance Technologies LLC acquired a new position in shares of Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 114,227 shares of the company’s stock, valued at approximately $233,000. Institutional investors own 1.61% of the company’s stock.

About Allarity Therapeutics

(Get Rating)

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.